Duloxetine HCL DR Capsules

Closed Solicitation Posted

This opportunity was awarded. See the award notice from .

Solicitation number
SPE2D2-25-R-0010
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Logistics Agency Troop Support Medical Supply Chain is soliciting proposals for Duloxetine HCL DR Capsules through solicitation SPE2D2-25-R-0010. The procurement covers eight line items for capsules in multiple dosage strengths (20mg, 30mg, 40mg, and 60mg) and various bottle sizes (30, 60, 90, and 1000 count) to serve the Department of Defense, Veterans Affairs, Bureau of Prisons, and Indian Health Service. Contractors must provide FDA-approved products that demonstrate therapeutic equivalence, comply with current Good Manufacturing Practices, and are compatible with automated dispensing units such as Baxter ATC Canisters and OptiFill. The acquisition will utilize lowest price technically acceptable (LPTA) evaluation criteria and requires comprehensive documentation including manufacturing facility details, past performance information, and detailed pricing data. The proposal submission deadline has been extended multiple times and is currently set for September 5, 2025, at 3:00 PM EST, with proposals required to be submitted electronically through the Defense Logistics Agency Internet Bid Board System (DIBBS).

This solicitation does not include any set-aside designations and no current incumbents or contractors are identified in the available documentation. The contract structure is a firm-fixed-price requirements contract for a one-year base period with four option years, not to exceed five years total, though specific award values are not disclosed. Estimated annual quantities vary significantly across line items, with the 30mg 90-count bottle representing the highest volume requirement at 155,424 bottles annually, while the 60mg 90-count bottle has the lowest estimated requirement at 4,161 bottles per year. Contract performance is scheduled to begin 45 calendar days after award, and the selected contractor will be required to provide quarterly sales reporting with a 0.5% cost recovery fee. The procurement will establish a national supply contract that supports pharmaceutical distribution through Prime Vendor contractors across multiple federal agencies.

Notice text

SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation

Files

Notice history

Notice Type Posted
Duloxetine HCL DR Capsules Award Award Notice
This notice Latest solicitation Solicitation
Duloxetine HCL DR Capsules Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Methylphenidate ER NAICS 325412 Medical Supply Chain No set-aside
Epinephrine Injector NAICS 325412 Medical Supply Chain No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity